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Our increasing understanding of cancer progression and dissemination has directed us 
from a tumour cell-centric model to one where the tumour microenvironment (local and 
systemic) is also recognised to play a pivotal role [1, 2].   This has been reflected in the 
numerous attempts to molecularly classify the intrinsic characteristics of the tumour cell over 
the past two decades resulting in subtypes for most common cancers.  For example, in 2015, 
a consortium proposed four consensus subtypes for colorectal cancer (MSI immune, 
canonical, metabolic, and mesenchymal) based on six classifications systems reported to have 
prognostic value [3].  Such studies have identified a stromal element as being associated with 
high risk of recurrent disease and poorer survival [4, 5].  However, despite compelling 
evidence supporting their use, such systems have largely failed to translate into routine 
pathological assessment, and their clinical utility remains to be fully determined and realised.   
The present study by Danielsen and colleagues in this issue adopts a pragmatic 
approach to incorporating characteristics of both the cancer cell and tumour 
microenvironment [6].  In a combined large retrospective cohort of 2624 patients with stage 
I-III colorectal cancer (from two previously described observational studies and the 
QUASAR 2 trial population) they developed and validated a prognostic score based on 
tumour cell ploidy status and the extent of tumour stromal infiltration. Utilising this score in 
the context of stage II disease, and controlling for a number of clinicopathological 
characteristics, it was possible to stratify patients into three clinically distinct groups with 
five-year cancer-specific survival of 90% (diploid tumour, low stroma), 83% (either non-
diploid or high stroma) and 73% (non-diploid and high stroma) respectively (P<0.001). The 
authors concluded that adoption of the ploidy/stroma score may be useful in selecting patients 
with stage II disease for adjuvant chemotherapy, where clinical benefit of additional therapy 
is often unclear.  For example, those patients deemed to have a good prognosis 
(approximately one third of the cohort) may avoid chemotherapy, the intermediate group 
(approximately half) could be considered for single-agent therapy, and the poor prognosis 
group offered oxaliplatin-based combination chemotherapy.  Indeed, such an approach may 
be more readily applicable to clinical practice than more comprehensive molecular and 
transcriptomic characterisation, and may ultimately aid in decision-making regarding 
prognosis and benefit of adjuvant therapy, particularly in patients with stage II disease. 
 
However, a number of technical and theoretical issues are worthy of discussion.  The authors 
employed digital pathology-based assessment to assess extent of tumour stromal infiltration 
and it remains to be determined whether the increased objectivity of such a system offers 
additional benefit over simple, manual semi-quantitative assessment as initially described by 
Mesker, and validated across a number of solid tumour types including colorectal cancer [4, 
5, 7, 8].  Of those tumour characteristics assessed in routine pathology only those patients 
recruited to QUASAR 2 (n=1092) had venous and lymphatic invasion assessed and only 
those patients from the Gloucester Colorectal Cancer Study cohort (n=954) had peritoneal 
involvement assessed, and it remains to be determined whether the ploidy/stroma score has 
prognostic value independent of optimal histopathological assessment. 
 
From a theoretical standpoint the omission of an assessment of the tumour inflammatory cell 
infiltrate may be problematical.  There is extensive evidence that the extent of inflammatory 
cell infiltrate has prognostic value in node negative colorectal cancer.  Indeed, reported 
studies date back almost 100 hundred years [9] and forms the basis of the Immunoscore [10, 
11] and scores based on the assessment of the extent of tumour inflammatory cell infiltrate 
and tumour stroma [12, 13].  Therefore, it remains to be determined whether ploidy offers 
additional prognostic value to these inflammation-based scores.  Given the increasing role of 
immunotherapy in patients with colorectal cancer [14], it would be anticipated that at least 
some measure of the local immune response be incorporated into novel, tumour 
microenvironment-based scoring systems and would also inform the nature of the tumour 
host interaction and outcome in patients with node negative colorectal cancer [15]. 
 Irrespective, the present report of Danielsen and colleagues will stimulate further 
studies into the routine assessment of the tumour-host interaction and outcome in patients 
with colorectal cancer.   
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